Myeloid Leukemia is an aggressive (fast-growing) disease in which too many myeloblasts (immature white blood cells that are not lymphoblasts) are found in the bone marrow and blood. Also called acute myeloblastic leukemia, acute myelogenous leukemia, acute nonlymphocytic leukemia, AML, and ANLL.
Why do some cancers come back? Sometimes, a treatment can effectively eliminate cancer cells to undetectable levels, but, if the treatment stops, cancer may return.
Fujitsu has announced the results of a joint research project it has been conducting with the Institute of Medical Science at the University of Tokyo since April 2018.
Your guacamole may hold the key to managing obesity and helping delay or prevent diabetes, according to a new study by a University of Guelph research team.
A new cancer clinical trial has opened at the M Health Fairview University of Minnesota Medical Center that leverages the groundbreaking research on stem cells and natural killer cells done at the Masonic Cancer Center and applies it to attack acute myeloid leukemia and B-cell lymphoma.
In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine have identified a new pathway that leads to the destruction of cancer cells.
A research team from the Johns Hopkins Kimmel Cancer Center reports it has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.
Sometimes the whole is greater than the sum of its parts. Researchers at Cold Spring Harbor Laboratory have discovered that two cell mutations, already harmful alone, enhance one another's effects, contributing to the development of the deadly blood cancer acute myeloid leukemia (AML).
A Waseda University-led research uncovered the molecular mechanism of how a particular cancer-causing oncogene could trigger an onset of acute myeloid leukemia (AML).
Of the various different functions that proteins perform in a cell, a crucial one is the recognition and transmission of certain "signals," collectively referred to as signal transduction.
A drug used to treat chronic myeloid leukemia appears to be more effective at stopping a type of medulloblastoma in mouse models than existing treatments for the deadly pediatric brain tumor, reports a multi-institutional team led by researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego.
The discovery of tri-specific natural killer engagers (TriKE™), a combination protein that bridges an immune cell and a tumor cell to drive tumor cell killing power exponentially, has led to a new Phase I, first-in-human study to treat leukemia.
A $5 million gift from the Edward P. Evans Foundation will create the Edward P. Evans Center for Myelodysplastic Syndromes at Dana-Farber Cancer Institute.
An estimated 61,780 new cases of leukemia will be diagnosed in the United States this year, with some 2,000 cases in New Jersey, according to the American Cancer Society.
Cancer cells form tumors. This statement, simple as it seems, hides a complex failure of normal immune responses that should eliminate tumor cells from the body before they ever form viable cancer masses.
Acute myeloid leukemia stem cells elude the body's immune cells by deactivating a danger detector. The underlying mechanisms and the potential new therapeutic approaches that this gives rise to have been detailed in the journal Nature by researchers from the University of Basel and University Hospital Basel in collaboration with colleagues in Germany.
A new study in JNCI Cancer Spectrum finds that dramatic increases in cancer survival in adolescents and young adults are undermined by continuing disparities by race, ethnicity, and socioeconomic status.
Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure.
A team of researchers from Indiana University and Memorial Sloan Kettering Cancer Center have been awarded a $4.1 million National Cancer Institute "Cancer Moonshot" grant to develop immunotherapy treatments for cancer in children and adolescents, especially those with leukemia.
With more targeted therapies being approved each year for cancer, the development of drug resistance to these agents is a growing concern.
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma.